The association between paternal prostate cancer and type 2 diabetes

Peter Meyer*1,2, Christine Zuern2, Norbert Hermanns3 and Thomas Haak3

Address: 1Institute of Molecular Medicine, Munich, Germany, 2Institute of Human Genetics, Division for Molecular Oncogenetics, University Hospital Tuebingen, Germany and 3Research Institute of the Diabetes Academy, Bad Mergentheim, Germany

Email: Peter Meyer* - peter.meyer@onkogenetik.de; Christine Zuern - christine.zuern@med.uni-tuebingen.de; Norbert Hermanns - hermanns@diabetes-zentrum.de; Thomas Haak - haak@diabetes-zentrum.de

* Corresponding author

Abstract

Objective: Increasing evidence indicates that type 2 diabetic patients are at elevated risk for developing different kinds of cancers. However, diabetes mellitus may be a protective factor for prostate cancer since both were found to be negatively associated. Based on the same genetic background, parents of diabetic patients might show similar risks concerning cancers.

Research design and methods: We conducted a case-control study, where family history of 794 type 2 diabetic cases and 775 non-diabetic controls was ascertained. Then, we expanded our study up to 801 type 2 diabetic cases and 1267 non-diabetic controls.

Results: Concerning the 794 type 2 diabetic patients and 775 controls, we observed that cancer of cervix uteri was elevated among mothers of controls (odds ratio (OR) 0.19; 95% confidence interval (CI) 0.02 to 0.88; p = 0.033). Mothers of diabetic patients showed an increased history of cancers of the liver and biliary tract (OR 5.23; 95% CI 1.87 to 19.9; p = 0.0009) and stomach (OR 3.84; 95% CI 1.47 to 12.4; p = 0.0049). Pancreatic cancers were found to be elevated in fathers of diabetic patients (OR 4.92; 95% CI 1.07 to 46.7; p = 0.039). Most notably, a lower number of prostate cancers was observed in fathers of diabetic patients (OR 0.47; 95% CI 0.22 to 0.94; p = 0.032). Since diabetic patients were 14.3 years older than the controls, higher levels of cancer history among parents of diabetic patients would have been expected. Thus, the observed lower level of history of prostate cancer can be regarded as highly reliable.

The analysis of 801 type 2 diabetics and 1267 controls showed that cancer of stomach was elevated among mothers of controls (OR 2.67; p = 0.0106). In addition, stomach cancers were found to be elevated in fathers of diabetic patients (OR 2.10; p = 0.0141). In accordance with the previous investigation, we again observed a lower number of prostate cancers in fathers of diabetic patients (OR 0.49; p = 0.0279).

However, the application of the statistical method of Mantel-Haenszel showed no significant result concerning any of the cancer histories.

Conclusion: Fathers of patients suffering from type 2 diabetes were diagnosed less frequently with prostate cancer compared to fathers of non-diabetic controls. As first-degree relatives, e.g. diabetic patients and their fathers, share 50% of their genes, it appears plausible that genetic factors may play an important role in the negative association between diabetes and prostate cancer. However, different statistic analyses showed controversial results concerning the effect of type 2 diabetes on prostate cancers.
Introduction
Diabetes has been associated with an increased risk of several human malignancies, including cancers of the pancreas [1,2], colon [3], endometrium [4,5], breast [6], kidney [7], liver [5,8], biliary tract [7] and esophagus [9].

However, a protective effect of diabetes mellitus on the risk of prostate cancer has been suggested by several [4,7], but not all studies [10,11] It has also been reported that only long-term diabetes has a protective effect on prostate cancer [12,13].

Recently a large, population-based cohort study in Sweden found a significantly decreased risk of prostate cancer among men hospitalized for diabetes mellitus [14]. Further evidence comes from Rosenberg et al. who reported that white type 2 diabetic patients appear to have a lower risk of prostate cancer [15]. However, a two hospital-based case-control study conducted in Italy and Greece could not confirm these findings [13].

The objective of our study was to analyze the relationship of a diabetic genetic background and cancer. In this report, we present results from a case-control study conducted in Germany, where we ascertained the family history of cancers in type 2 diabetic patients and controls. In our investigations, we evaluated whether paternal history of prostate cancer was decreased among type 2 diabetic patients.

Materials and methods
From September 2001 to February 2002, cases and controls were recruited in the southern part of Germany. The first case group consisted of 794 patients (median age 62.3 years), the second of 801 patients, who were hospitalized with a primary or secondary diagnosis of type 2 diabetes according to the International Classification of Diseases (ICD-10) in the Diabetes Hospital Bad Mergenheim, Germany. 775 control subjects (median age 47.9 years) and 1267 controls respectively were selected from the Center of blood donation Tuebingen, Germany. It was required that the controls never had been diagnosed with type 2 diabetes. This was verified by the measurement of HbA1c, the regular check on blood glucose by the Center of blood donation and a negative history of diabetes in the interview.

A complete interview was obtained from all cases and controls by two specifically trained interviewers. The interviews were based on structured questionnaires which included family history of different kinds of cancers, e.g. cancers of the prostate, breast, colon and rectum, uterus, kidney, pancreas, esophagus, liver and biliary tract. All paternal and maternal types of cancer were considered in the statistical analysis, except data of participants being uncertain about their parental cancer history. Since we concentrated on the relationship of paternal prostate cancer and type 2 diabetes, the other cancers, which were found to be statistically significant, must be regarded as descriptive results. Therefore, an adjustment of p-values for multiple testing was not done. Odds ratios, 95% confidence intervals and p-values were calculated using the statistics package JMP Version 3. In order to obtain estimates of odds ratios also in tables with zero counts, we added 0.5 to all table entries. Based on significantly different median ages of patients and controls, terziles were built and the effect of age on the numbers of cancers was tested. We found that age had no influence on the numbers of cancers and is no biasing effect on the results.

Results
The prevalence of history of paternal and maternal cancers and the corresponding p-values, which were generated with 794 patients and 775 controls, are shown in Table 1. Statistically significant differences in cancer histories were observed in both fathers and mothers of diabetic patients and controls. These differences were found in cancers of cervix uteri, liver and biliary tract, stomach, pancreas and prostate.

We found a significantly increased cancer history (OR 0.19; 95% CI 0.02 to 0.88; p = 0.033) for cancer of cervix uteri in mothers of controls (0.91%) compared with mothers of diabetic patients (0.13%). In contrast, mothers of diabetic patients showed an elevated history of cancer (OR 5.23; 95% CI 1.89 to 19.9; p = 0.0009) of the liver and biliary tract (2.27%; 0.39% in mothers of diabetic patients and of controls, respectively). In addition, stomach cancer history was also more frequent (OR 3.84; 95% CI 1.47 to 12.4; p = 0.005) in mothers of diabetic patients (2.14%) compared to mothers of controls (0.52%).

Cancer history was significantly elevated (OR 4.92; 95% CI 1.07 to 46.7; p = 0.039) in fathers of diabetic patients concerning pancreatic cancer (0.88% compared with 0.13% in fathers of controls). Most notably, the paternal prostate cancer history was decreased (OR 0.47; 95% CI 0.22 to 0.94; p = 0.032) among fathers of diabetic patients. 1.39% of the fathers of the cases were reported to suffer from prostate cancer, in contrast to 2.97% of the fathers of the controls. There was no statistically significant difference between the histories of other malignancies in both groups.

Subsequently, the enlarged study included a total sample of 801 type 2 diabetes patients and 1267 controls. Statistically significant differences in cancer histories, which are presented in Table 2, were found in cancers of stomach and prostate.
Stomach cancer was significantly higher among mothers of controls (OR 2.67; p = 0.0106) and among fathers of diabetic patients (OR 2.10; p = 0.0141). Interestingly, prostate cancer in fathers of type 2 diabetic patients showed again a lower number than in fathers of controls (OR 0.49; p = 0.0279).

However, when the Mantel-Haenszel statistics was applied, no statistically significant differences between cancer histories were observed (Table 3).

**Discussion**

The main findings in this case-control study conducted in Southern Germany demonstrate that prostate cancer is reduced in fathers of type 2 diabetic patients. Furthermore, the history of cancers of the liver, biliary tract and stomach was increased in mothers of controls. Besides, we showed that the history of pancreatic cancer was higher in fathers of diabetic patients. On the basis of epidemiological and biological data we had selected prostate cancer as the main point of investigation in our study. The observed associations of other types of cancers with diabetes are presented as secondary results. Therefore, an adjustment of p-values for multiple testing was not done.

### Table 1: Frequencies of cancers in parents of 794 diabetic patients and 775 controls

| Type of cancer | Fathers of diabetic patients | Fathers of controls | Mothers of diabetic patients | Mothers of controls |
|---------------|-----------------------------|---------------------|-----------------------------|---------------------|
| Basalioma     | 0.00                        | 0.00                | 0.98                        | 0.13                |
| Brain & other nervous system | 0.63                        | 0.39                | 0.53                        | 1.54                |
| Breast        | 0.00                        | 0.00                | 0.98                        | 0.13                |
| Cervix uteri  | -                           | -                   | 0.13                        | 0.033               |
| Colon & rectum | 1.51                        | 2.58                | 0.14                        | 2.14                |
| Corpus uteri  | -                           | -                   | 0.13                        | 0.00                |
| Esophagus     | 0.13                        | 0.26                | 0.60                        | 0.58                |
| M. Hodgkin    | 0.13                        | 0.00                | 0.48                        | 0.26                |
| Kidney & renal pelvis | 0.13                        | 0.52                | 0.20                        | 0.13                |
| Larynx        | 0.50                        | 0.52                | 0.97                        | 0.25                |
| Leukemia      | 0.13                        | 0.13                | 0.98                        | 0.25                |
| Liver & biliary tract | 1.01                        | 1.16                | 0.77                        | 0.87                |
| Lung & bronchus | 2.52                        | 2.71                | 0.81                        | 0.93                |
| Melanoma      | 0.00                        | 0.26                | 0.22                        | 0.19                |
| NHL           | 0.00                        | 0.00                | 0.98                        | 0.25                |
| Oral cavity & pharynx | 0.50                        | 0.52                | 0.97                        | 0.98                |
| Ovary         | -                           | -                   | 0.38                        | 0.26                |
| Pancreas      | 0.88                        | 0.13                | 0.039                       | 4.92                |
| Prostate      | 1.39                        | 2.97                | 0.032                       | 0.47                |
| Stomach       | 3.15                        | 1.94                | 0.13                        | 1.63                |
| Testis        | 0.38                        | 0.26                | 0.70                        | 1.37                |
| Thyroid       | 0.00                        | 0.13                | 0.46                        | 0.32                |
| Urinary bladder | 0.13                        | 0.52                | 0.20                        | 0.32                |

p-values < 0.05 are typed in bold letters; in order to estimate odds ratios (OR) even in the presence of zero counts the value of 0.5 was added to all counts.
lower history of prostate cancer in fathers of diabetic patients can be connected with common ways of nutrition as well as shared genetic factors since first grade relatives have 50% of their genes in common. Thus, our findings confirm the hypothesis of a diabetes protective effect on prostate cancer and emphasise the important role of genetic factors in this progress. Since the median age of the case group was substantial higher than the median age of the controls, fathers of diabetic patients even had a higher possibility of developing prostate cancer as its incidence rises by age. Therefore, the observed reduction of paternal prostate cancer is unlikely to be due to bias on the different median ages of the case and control groups.

This protective role of diabetes on prostate cancer may be explained in terms of decreased levels of insulin-like growth factor I (IGF-I) which have been reported in diabetic patients with hyperinsulinemia by some studies [16-19] In addition, chronic hyperinsulinemia was found to be inversely associated with plasma testosterone levels [20]. Clinical and epidemiological observations suggest that both IGF-I and androgens may enhance prostate tumour development [20-22]. In view of the alterations in serum testosterone and IGF-1 concentrations caused by diabetes mellitus, a reduction of prostate cancer risk among humans with a genetic background of diabetes appears biologically plausible [16].

Another possible explanation for the diabetes protective effect on prostate cancer could be the existence of a genetic factor that on one hand raises the risk of diabetes while on the other hand lowering the prostate cancer risk. Genetic variation in PPAR-gamma (MIM# 601487) e.g. was found to be associated with a higher incidence of diabetes mellitus [23,24] In addition, PPAR-gamma was shown to be expressed in human prostate adenocarcinomas and derived cell lines. Moreover, the activation of this receptor with specific ligands leads to an inhibition of prostate cancer cell growth [25].

In conclusion, we report for the first time that fathers of type 2 diabetic patients show decreased history of prostate cancer. A protective effect of diabetes predisposing genetic factors on prostate cancer genesis may be assumed.

**Abbreviations**

CI (confidence interval)

HbA1c (glycosylated hemoglobin)
IGF-1 (insulin-like growth factor I)

OR (odds ratio)

PPAR-gamma (peroxisome proliferator-activated receptor-gamma)

References

1. Chow WH, Gridley G, Nyren O, Linet MS, Ekblom A, Fraumeni JF Jr, Cancer HO: Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Canc Inst 1995, 87:930-931.

2. Everhart J, Wright D: Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995, 273:1605-1609.

3. Hu FB, Manson JE, Liu S, Hunter DJ, Colditz GA, Michels KB, Speizer FE, Giovannucci E: Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Canc Inst 1999, 91:542-547.

4. Adami HO, McLaughlin J, Ekblom A, Berne C, Silverman D, Hacker D, Asson I: Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991, 2:307-314.

5. La Vecchia C, Negri E, Franceschi S, D’Avanzo B, Boyle P: A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994, 70:950-953.

6. Weiderpass E, Grinyi G, Persson I, Nyren O, Ekblom A, Adami HO: Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer 1997, 71:360-363.

7. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keenh S, Borch-Johnsen K, Olsen JH: Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Canc Inst 1997, 89:1360-1365.

8. Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekblom A, Wolk A, McLaughlin JK, Fraumeni JF Jr: Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Canc Inst 1996, 88:1472-1477.

9. Lagergren J, Bergstrom R, Nyren O: Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999, 130:883-890.

10. McLaughlin JK, Mink PJ, Natarajan L, Palu S: Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse and physical activity. Cancer Epidemiol Biomarkers Prev 1995, 4:807-811.

11. Coughlin SS, Neaton JD, Sengupta A: Cigarette smoking as a predictor of death from prostate cancer in 348,874 men screened for the Multiple Risk Factor Intervention Trial. Ann J Epidemiol 1996, 143:1002-1006.

12. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC: Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1999, 9:3-9.

13. Tavani A, Gallus S, Bosetti C, Tzonou A, Lagiou P, Negri E, Trichopoulos D, La Vecchia C: Diabetes and the risk of prostate cancer. Eur J Cancer Prev 2002, 11:125-128.

14. Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO: Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer 2002, 102:258-261.

15. Rosenberg D, Neugut A, Ahsan H, Shea S: Diabetes mellitus and the risk of prostate cancer. Cancer Invest 2002, 20:157-165.

16. Mantzoros CS, Tzonou A, Signorello LB, Stampfer MJ, Trichopoulos D, Adami HO: Insulin-like growth factor I in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997, 76:1115-1118.

17. Kaaks R, Lukanova A: Energy balance and cancer: the role of insulin-like growth factor-I. Proc Nutr Soc 2001, 60:91-106.

18. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279:563-566.

19. Pollak M: Insulin-like growth factors and prostate cancer. Epidemiol Rev 2001, 23:59-66.

20. Kaaks R, Lukanova A, Sommersberg B: Plasma androgens, IGF-I, body size, and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis 2000, 3:157-172.

21. Bosland MC: The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 2000:39-66.

22. Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Pears TR, Madigan MP, Ziegler RG, Fraumeni JF Jr, Hsing AW: Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2001, 10:421-427.

23. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaftner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES: The common PPAR-gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000, 26:76-80.

24. Hegele RA, Cao H, Harris SB, Zinman B, Hanley AJ, Anderson CM: Peroxisome proliferator-activated receptor-gamma2 P12A and type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab 2005, 80:2014-2019.

25. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kanoff PW: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 2000, 97:10990-10995.